Human papillomavirus is a genus of papilloma vacuole virus A belonging to the family Papillomavirus. It is a spherical DNA virus that can cause the squamous epithelium of human skin and mucous membranes to proliferate. It manifests as common warts, genital warts (condyloma acuminatum) and other symptoms. With the rapid increase in the incidence of condyloma acuminata in sexually transmitted diseases and the increase in cervical cancer and anal cancer, human papillomavirus (hpv) infection has attracted more and more attention.
Papules the size of rice grains, with obvious keratinization on the surface, rough and uneven, thorn-like top, hard texture
Diseases in special parts: multiple small warts on the fingers, around the toenails, the neck of the foot and the plantar area, and the eyelids
Benign manifestations of external genital diseases
Verrucous lesions on the surface of the oral mucosa, recurrent respiratory papillomatosis, etc.
After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:
1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.
2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.
3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108
4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.
5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment
After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:
1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.
2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.
3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108
4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.
5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment
After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:
1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.
2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.
3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108
4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.
5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
